{"Symbol": "ALLO", "AssetType": "Common Stock", "Name": "Allogene Therapeutics Inc", "Description": "Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.", "CIK": "1737287", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080", "OfficialSite": "https://allogene.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "404514000", "EBITDA": "-212484000", "PERatio": "None", "PEGRatio": "None", "BookValue": "1.413", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.98", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.273", "ReturnOnEquityTTM": "-0.544", "RevenueTTM": "0", "GrossProfitTTM": "-166492000", "DilutedEPSTTM": "-0.98", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-1", "AnalystTargetPrice": "7.38", "AnalystRatingStrongBuy": "3", "AnalystRatingBuy": "10", "AnalystRatingHold": "1", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "1", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "11631.14", "PriceToBookRatio": "1.283", "EVToRevenue": "3859.62", "EVToEBITDA": "-1.039", "Beta": "0.604", "52WeekHigh": "3.78", "52WeekLow": "0.862", "50DayMovingAverage": "1.55", "200DayMovingAverage": "1.313", "SharesOutstanding": "224730000", "SharesFloat": "154369000", "PercentInsiders": "16.630", "PercentInstitutions": "67.301", "DividendDate": "None", "ExDividendDate": "None"}